Physician profile
Khalida Khaled
NPI 1952796302
$11,821.38
in general payments reported to CMS, 2019-2025
26 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $43.28 · 2021: $5,343 · 2022: $4,453 · 2023: $1,073 · 2024: $383 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Travel and Lodging: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.10 |
| Travel and Lodging | $374.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,737.34 | 2019-2024 | Cardiomems |
| Medtronic, INC. | $2,196.89 | 2021-2023 | Corevalve Evolut R |
| Boston Scientific Corporation | $1,732.11 | 2021-2022 | |
| Edwards Lifesciences Corporation | $1,221.59 | 2022-2024 | |
| Inari Medical, INC. | $285.12 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $146.66 | 2021-2025 | Farxiga |
| Amgen INC. | $140.48 | 2019-2022 | |
| Surmodics, INC. | $133.85 | 2022 | |
| Penumbra, INC. | $133.66 | 2022 | |
| Chiesi USA, INC. | $132.02 | 2021 | |
| Pfizer INC. | $117.30 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $108.71 | 2019 | |
| W. L. Gore & Associates, INC. | $96.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $94.87 | 2022-2023 | Xarelto |
| Philips North America LLC | $94.40 | 2025 | Laser Cvx300 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.30 | 2025 | Lifevest |
| Shockwave Medical, INC | $77.40 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $72.85 | 2019-2024 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $58.83 | 2019-2020 | |
| Biotronik INC. | $33.90 | 2021-2022 | |
| Cvrx, INC. | $24.19 | 2024 | Barostim Neo System |
| Lantheus Medical Imaging, INC. | $23.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.89 | 2022 | |
| Merck Sharp & Dohme LLC | $17.50 | 2025 | Verquvo |
| Novo Nordisk INC | $16.37 | 2024 | Rybelsus, Ozempic |
| Vifor Pharma, INC. | $15.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalida Khaled listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.